AXTI
AXT, Inc.
AXTI has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
AXTI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AXTI's revenue, profitability, cash flow and balance sheet are all currently strong.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
AXTI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $5.95 | -86% |
| Forward | 18x | $43.54 | — |
| Fair | 23x | $9.92 | -77% |
| Expensive | 96x | $42.09 | -3.3% |
| Current | 99x | $43.54 | — |
Historical ranges are pointers, not guarantees.
AXTI's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its fair range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over AXTI in the historical PE scenario, which offers more potential upside but is not a forecast.
AXTI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
AXTI has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
AXTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +445% |
| Q3 2026 | $0.44 | +$0.95 |
| Q2 2026 | $0.01 | +$0.55 |
| Q1 2026 | -$0.32 | +$0.10 |
| Q4 2025 | -$0.49 | -$0.22 |
| Q3 2025 | -$0.51 | -$0.26 |
| Q2 2025 | -$0.54 | -$0.22 |
| Q1 2025 | -$0.42 | -$0.02 |
| Q4 2024 | -$0.27 | +$0.16 |
AXTI has returned to profit: it earned $0.44 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over AXTI on earnings, with more consistent year-over-year improvement.
AXTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +163% |
| Q2 2026 | $47.6M | +165% |
| Q1 2026 | $26.9M | +39% |
| Q4 2025 | $23M | -8.2% |
| Q3 2025 | $28M | +18% |
| Q2 2025 | $18M | -36% |
| Q1 2025 | $19.4M | -15% |
| Q4 2024 | $25.1M | +23% |
AXTI's revenue is growing: $73M last quarter, up 163% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +43 points |
| Q2 2026 | 22% | +59 points |
| Q1 2026 | -5.9% | +47 points |
| Q4 2025 | -17% | +7.9 points |
| Q3 2025 | -4% | +10 points |
| Q2 2025 | -38% | -31 points |
| Q1 2025 | -53% | -38 points |
| Q4 2024 | -25% | -7.1 points |
AXTI has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
AXTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.7M | +$99M |
| Q2 2026 | $3.6M | +$8.4M |
| Q1 2026 | -$13.1M | -$9.2M |
| Q4 2025 | $1.3M | +14% |
| Q3 2025 | -$11.3M | -$5M |
| Q2 2025 | -$4.9M | -949% |
| Q1 2025 | -$3.9M | +$9.3M |
| Q4 2024 | $1.1M | -48% |
AXTI's free cash flow has turned positive after six years mostly in the red: $79M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over AXTI on cash flow, with more consistent year-over-year improvement.
AXTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.4M shares |
| 1 year | +51% | +22.2M shares |
| 3 years | +55% | +23.3M shares |
| 5 years | +54% | +23.1M shares |
| Available history | +67% | +26.4M shares |
AXTI has 66M diluted shares, up 51% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over AXTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
AXTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.2x | Net Cash |
| Q2 2026 | -24.4x | Net Cash |
| Q2 2023 | 93.9x | High |
| Q1 2023 | 5.5x | High |
| Q4 2022 | 2.9x | Moderate |
| Q3 2022 | 2.2x | Moderate |
| Q2 2022 | -0.4x | Net Cash |
| Q1 2022 | -0.5x | Net Cash |
AXTI has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
AXTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 15.1 | Oversold |
AXTI's weekly RSI is 43 (neutral) and its Stochastic is 15 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
AXTI PE vs Technology Sector
| Metric | AXTI | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 28x | 255% above |
| PE % | 83 | 35 | 48 pts above |
AXTI is trading at 99x earnings, a 255% premium to the Technology sector's median of 28x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over AXTI on valuation relative to its sector.
AXTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.3 | 27% below |
| 20 week MA | $61.9 | 30% below |
| 50 week MA | $58.0 | 25% below |
| 100 week MA | $30.5 | 43% above |
| 200 week MA | $16.8 | 159% above |
AXTI has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
AXTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.04 | $9.64 | +139% |
| 2021 | $9.64 | $8.80 | -8.7% |
| 2022 | $8.80 | $4.40 | -50% |
| 2023 | $4.40 | $2.40 | -45% |
| 2024 | $2.40 | $2.28 | -5% |
| 2025 | $2.28 | $15.4 | +574% |
| 2026 YTD | $15.4 | $43.5 | +183% |
AXTI has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.